Detail akcie Organon Rg-WI online

Business Summary: Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Organon & Co revenues decreased 4% to $1.46B. Net income increased 68% to $146M. Revenues reflect Women’s Health segment decrease of 16% to $389M, Respiratory segment decrease of 22% to $183M, United States segment decrease of 13% to $358M, Asia Pacific and Japan segment decrease of 10% to $226M. Net income reflects Other (income) expense, net - Balancin decrease from $1M (expense) to $103M (income).